Syngene International Ltd
Ticker: SYNGENE
Decent
72/100
☆ Add to Watchlist
Investing Reference
Price
628.10
Market Cap
25229.06
Debt/Equity
0.1223
ROE %
11.046
PB
5.3374
Promoter %
52.684
Pledge %
0.000
1Y Rev Growth %
4.666
5Y Rev Growth %
11.592
NP Margin %
13.245
NP Margin 5Y Avg %
14.870
Trading Reference
1M Return %
-5.527
6M Return %
-12.933
1Y Return %
-29.176
% Away 52W High
52.937
% Away 52W Low
4.762
Daily Volume
640076
Investment Verdict
Risky
Score 58/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Avoid
Score 21/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Syngene International Ltd is likely to face resistance around the ₹600 level, with support at ₹500. Given the current trend and volume patterns, there is a potential upside of 15% if it breaks above resistance, while downside risk is estimated at 10% if it falls below support.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
S
Sona BLW Precision Forgings Ltd
Sona BLW Precision Forgings Ltd shows promise in a growing sector, but faces challenges in profitability and valuation metrics.
View details
J
J B Chemicals and Pharmaceuticals Ltd
J B Chemicals and Pharmaceuticals Ltd shows decent potential with a stable growth outlook, but investors should be cautious of execution risks and valuation metrics.
View details
B
Bandhan Bank Ltd
Bandhan Bank Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Investors should be cautious.
View details
P
Piramal Pharma Ltd
Piramal Pharma Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
E
Emami Ltd
Emami Ltd shows potential in the FMCG sector with decent growth prospects, but faces challenges in profitability and execution risks.
View details
S
Star Health and Allied Insurance Company Ltd
Star Health and Allied Insurance Company Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
I
IRB Infrastructure Developers Ltd
IRB Infrastructure Developers Ltd shows potential in a growing sector, but faces challenges in execution and valuation.
View details
I
Inventurus Knowledge Solutions Ltd
The stock presents several risks with inconsistent growth and profitability metrics, alongside valuation concerns. Caution is advised for potential investors.
View details
I
Inox Wind Ltd
Inox Wind Ltd faces several challenges, including inconsistent growth and market competition, making it a risky investment at this time.
View details
N
National Securities Depository Ltd
National Securities Depository Ltd shows decent fundamentals with stable growth prospects, but faces some execution risks and competition.
View details
E
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals shows potential for growth, but faces several challenges that could impact its performance.
View details
S
Shyam Metalics and Energy Ltd
Shyam Metalics and Energy Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
Z
ZF Commercial Vehicle Control Systems India Ltd
ZF Commercial Vehicle Control Systems India Ltd shows potential for growth in a transitioning sector, but faces challenges in profitability and valuation metrics.
View details
F
Firstsource Solutions Ltd
Firstsource Solutions Ltd shows potential with consistent growth but faces challenges in profitability and competitive pressures.
View details
E
EIH Ltd
EIH Ltd shows potential in a recovering sector but faces challenges in growth consistency and market competition.
View details
A
Anand Rathi Wealth Ltd
Anand Rathi Wealth Ltd shows potential for growth in a competitive sector, but faces challenges in profitability and valuation metrics.
View details
Business Overview
Syngene International Ltd is a leading global contract research and manufacturing organization based in India, catering to pharmaceutical, biotechnology, and agrochemical sectors. With a strong focus on innovation and quality, Syngene partners with clients to accelerate drug development and enhance productivity. This matters as it plays a crucial role in advancing healthcare solutions and supports the growing demand for biopharmaceuticals.
- Established leader in contract research and manufacturing
- Serves diverse sectors: pharma, biotech, agrochemicals
- Focus on innovation and quality assurance
- Strong partnerships with global clients
- Contributes to healthcare advancements in India and beyond
Investment Thesis
Syngene International Ltd stands out as a compelling investment due to its strong promoter group, robust growth in digital services, and attractive valuation compared to peers. The company's credibility and strategic positioning in the biotech sector make it a promising choice for investors seeking long-term growth.
- Backed by the reputable Biocon Group, ensuring strong governance and strategic support.
- Significant growth potential in digital services, catering to the evolving needs of the pharma industry.
- Currently trading at a favorable valuation compared to industry peers, presenting a buying opportunity.
- Diversified service offerings mitigate risks and enhance revenue streams.
- Strong financial performance and consistent growth trajectory reinforce investor confidence.
Opportunity vs Risk
Opportunities
- Strong growth in biotech sector
- Expanding global client base
- Innovative research and development
- Strategic partnerships with pharma
- Increasing demand for contract research
Risks ⚠️
- Regulatory changes impacting operations
- High competition in biotech
- Dependence on key clients
- Market volatility affecting stock price
- Economic downturns impacting funding
Peer Perspective
Syngene International Ltd trades at a discount to peers like Dr. Reddy's and Cipla, reflecting concerns over margin stability. A consistent growth trajectory and improved profitability could trigger a rerating in its valuation.
Future Outlook
Syngene International Ltd is well-positioned for growth, driven by strong demand in the biotech sector. However, successful execution of its strategic initiatives and effective cost control will be crucial for maximizing shareholder value.
AI FAQs for Retail Users
- Q: What does Syngene International Ltd do?A: Syngene is a biopharmaceutical company providing contract research and manufacturing services.
- Q: Is Syngene a profitable company?A: Syngene has reported profits in recent years, but profitability can vary based on market conditions.
- Q: What are the main risks of investing in Syngene?A: Risks include market competition, regulatory changes, and dependence on client contracts.
- Q: How can I invest in Syngene shares?A: You can buy Syngene shares through a registered stockbroker or online trading platform.
- Q: What is the outlook for Syngene's growth?A: Syngene's growth depends on industry demand and its ability to innovate and expand services.
📊 Stock Investment Checklist (100 Points)
Syngene International Ltd • Updated: 2025-09-18 01:13:55
-
10BusinessHighSyngene operates in the biopharmaceutical sector, which is future-ready with a clear business model and some competitive advantages.
-
10GrowthHighThe company has shown consistent revenue and profit growth over the past few years.
-
10ProfitabilityHighROE and ROCE are healthy, and operating cash flow is strong relative to net profit.
-
8ValuationHighValuation metrics like P/E and P/B are reasonable compared to peers, but slightly on the higher side.
-
7BalanceHighThe balance sheet is strong with low debt levels and good liquidity.
-
9GovernanceHighPromoter holding is stable with no significant pledging, and disclosures are transparent.
-
6DriversGoodThere are growth catalysts in the pipeline, but execution risks remain.
-
5TechnicalsGoodMarket sentiment is neutral with moderate liquidity and price action.
Final Score & Verdict
Score 72 / 100
• Decent
Syngene International Ltd shows a decent investment profile with consistent growth and profitability metrics, though valuation is slightly elevated.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 80/100
- Profitability: 70/100
- Governance: 65/100
- Market Confidence: 75/100